Abraham C R
Department of Neurobiology, Harvard Medical School, Boston, MA 02115.
Neurobiol Aging. 1989 Sep-Oct;10(5):463-5; discussion 477-8. doi: 10.1016/0197-4580(89)90097-3.
Recently, protease inhibitors have been recognized as potential contributors to the pathogenesis of Alzheimer's disease. In this role, they could mediate an exaggerated regenerative response in the brain, participate as acute phase reactants, or be involved in the aberrant proteolytic processing of the amyloid proteins. Protease inhibitors are, therefore, attractive targets for drug intervention in Alzheimer's disease.
最近，蛋白酶抑制剂已被认为是阿尔茨海默病发病机制的潜在促成因素。在这一作用中，它们可能介导大脑中过度的再生反应，作为急性期反应物参与其中，或参与淀粉样蛋白的异常蛋白水解过程。因此，蛋白酶抑制剂是阿尔茨海默病药物干预的有吸引力的靶点。
